They need to highlight the CLBP. They appear to have spent too much time and effort and attention on aGvHD.
They should have pursued a deal like they did with Novatis to sell the product in different markets.
Clear roadmap to more revenue growth by exploring different markets should be coming from the CEO. Only waiting for FDA's verdict not enough.
Why did they not pursue any other deals after the Novatis had fallen apart?
CLBP has to be the CEO's core focus moving forward.
rexlemestrocel-L in the treatment of chronic low back pain (CLBP), page-6
-
- There are more pages in this discussion • 19 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
-0.025(2.17%) |
Mkt cap ! $1.284B | |||
| Open | High | Low | Value | Volume |
| $1.15 | $1.16 | $1.11 | $7.363M | 6.488M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 94863 | $1.13 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.13 | 5000 | 2 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |